InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,392.00
(
0.23%
)
Post# of 647879
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

$oldier Hard

Send PM Follow Ignore
Followers 1870
Posts 90259
Boards Moderated 1
Alias Born 09/02/2006

$oldier Hard

Member Level

Re: oldberkeley post# 323780

Thursday, 09/04/2014 7:06:56 PM

Thursday, September 04, 2014 7:06:56 PM

Post# of 647879
ACST, I did see this when they announced there fins back in July. They always are but wth.

Top-line results for the recently completed TRIFECTA and PK trial are expected by the end of September 2014, with full data for both trials coming out in the following quarter. Top-line data for the TRIFECTA trial will include the efficacy of CaPre(R) in lowering triglycerides, along with its impact on other lipid markers, including high-density lipoprotein (HDL) and non-HDL as well as low-density lipoprotein (LDL).

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up